CN106690321A - 一种增强免疫力的口服含片 - Google Patents
一种增强免疫力的口服含片 Download PDFInfo
- Publication number
- CN106690321A CN106690321A CN201710012730.7A CN201710012730A CN106690321A CN 106690321 A CN106690321 A CN 106690321A CN 201710012730 A CN201710012730 A CN 201710012730A CN 106690321 A CN106690321 A CN 106690321A
- Authority
- CN
- China
- Prior art keywords
- parts
- strengthen immunity
- buccal tablet
- oral buccal
- sweet wormwood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 39
- 229940100629 oral lozenge Drugs 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 37
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 26
- 240000000011 Artemisia annua Species 0.000 claims abstract description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- 210000000130 stem cell Anatomy 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 19
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 13
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 10
- 239000003765 sweetening agent Substances 0.000 claims abstract description 10
- 229940046011 buccal tablet Drugs 0.000 claims description 24
- 239000006189 buccal tablet Substances 0.000 claims description 24
- 239000004378 Glycyrrhizin Substances 0.000 claims description 12
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 12
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 12
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 12
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 102000006463 Talin Human genes 0.000 claims description 3
- 108010083809 Talin Proteins 0.000 claims description 3
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 241001409321 Siraitia grosvenorii Species 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 239000007937 lozenge Substances 0.000 abstract description 6
- 238000004113 cell culture Methods 0.000 abstract description 3
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 235000015165 citric acid Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 244000185386 Thladiantha grosvenorii Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- RXHIKAIVEMAPRU-JRIGQVHBSA-N sequiterpene Natural products C1=C(C)[C@@H](OC(C)=O)[C@H](O)[C@@]2(O)[C@H](C)CC[C@@H](C(C)=C)[C@H]21 RXHIKAIVEMAPRU-JRIGQVHBSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000021282 Sterculia Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008125 glucin Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229930183339 qinghaosu Natural products 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940059107 sterculia Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种增强免疫力的口服含片，其特征在于，由以下重量份比的原料组成：青蒿干细胞干粉10‑30份，清凉剂0.1‑0.4份，甜味剂0.2‑0.6份，麦芽糊精1‑5份，柠檬酸0.8‑2份，硬脂酸镁0.8‑2份，水2‑6份。与现有技术相比，本发明的有益效果为：通过培养青蒿干细胞提取其细胞培养物并制备成干粉，压制成含片，适口性好，方便携带、食用，且可以现在增强免疫力。
Description
技术领域
本发明属于保健品技术领域，具体涉及一种增强免疫力的口服含片。
背景技术
现代免疫学认为，免疫力是人体识别和排除“异己”的生理反应。人体内执行这一功能的是免疫系统。免疫系统由免疫器官、免疫细胞和免疫因子组成。免疫细胞、免疫因子分布全身，形成一个相互制约的网络，主宰人体的免疫功能，抵抗细菌、病毒的入侵，清除体内代谢废物，维持机体内环境的稳定。免疫力低下的身体极易招致细菌、病毒、真菌等感染，容易生病，会加重机体的消耗，导致体质虚弱、营养不良、精神萎靡、疲乏无力、食欲降低等，严重免疫力下降的还会诱发重大疾病。随着生活节奏的加快，人们的工作、学习压力加大，同时由于多数人长期缺乏体育锻炼，免疫力低下人群越来越多，增强免疫力已刻不容缓。
专利号CN101664181A公开一种增强免疫力、清咽利喉、消除咽喉肿痛的口服含片，其主要成分按重量份数配比为：绞股蓝30-300，西洋参5-50，胖大海12-120，薄荷脑0.001-0.02。
专利号CN102949522A公开一种用于增强免疫力的药物组合物及其含片制备方法，该药物组合物含有的成分及其重量配比为：西洋参60份、枸杞子40份。
现有技术中增强免疫力的含片至少需要依赖2种功效性成分，成分多、价格贵，且都是通过原材料直接粉碎制成，利用率低，难吸收，提高免疫力效果不尽人意。
发明内容
针对现有技术中存在的上述问题，本发明的目的在于提供一种增强免疫力的口服含片，以期仅通过一种功效性成分青蒿干细胞干粉达到增强免疫力的效果。
为实现上述发明目的，本发明采用的技术方案如下：
一种增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉10-30份，清凉剂0.1-0.4份，甜味剂0.2-0.6份，麦芽糊精1-5份，柠檬酸0.8-2份，硬脂酸镁0.8-2份，水2-6份。
进一步的，所述增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉12-28份，清凉剂0.2-0.3份，甜味剂0.3-0.5份，麦芽糊精2-4份，柠檬酸1-1.8份，硬脂酸镁1-1.8份，水3-5份。
所述清凉剂为薄荷脑。
所述甜味剂为甘草甜素、甜菊苷、甜茶素、罗汉果甜或索马甜。
所述甘草甜素的提取方法为：先将甘草切细，和6-8倍量的冷水，浸泡1-1.5d,过滤得到滤液和滤渣。往滤渣中再加入4-6倍量的冷水浸泡10-12h,再次过滤得到滤液。合并两次滤液、蒸发浓缩、冷却,加人乙醇并在低温下放置2.5-3d,将混合液过滤再次蒸发浓缩滤液得到黑褐色粘稠状抽提液。干燥失重在35％以下,甘草抽提液再次浓缩干燥后生成甘草甜素粗结晶,最后将此粗结晶在稀乙醇溶液中进行重结晶即可得到精制的甘草甜素产品。
所述增强免疫力的口服含片制备方法为：
(1)制粒，将青蒿干细胞干粉、甜味剂、麦芽糊精、柠檬酸、水按重量份比混合好放入制粒机，筛底选20-30目筛；
(2)干燥，制粒结束后，迅速在50-60℃下干燥，当水分在3％～6％之间时，结束干燥；
(3)整粒，将干燥好的颗粒过20-30目筛，使颗粒粒度分布均匀；
(4)混合，加入相应重量份比的清凉剂，硬脂酸镁，在V型混合机中混合5-8min后，装袋备用；
(5)压片，放入进料斗，压片至片剂硬度在80N～110N之间即可。
青蒿，为菊科植物黄花蒿(Artemisia annua L.)的干燥地上部分，是我国的传统中药，具有广泛的药理作用，其主要成分青蒿素是一种含有过氧基团的新型倍半萜内酯化合物，具有起效快、疗效好、毒性低的特点，被世界卫生组织称为是世界上唯一有效的抗疟药物。青蒿其它药理作用还有:抗血吸虫作用，抗菌作用，抗内毒素作用，消炎镇痛等。青蒿中化合物主要分为两大类:一类是挥发性成分，另一类是非挥发性成分。青蒿挥发性成分主要是挥发油，由单萜、单萜氧化物、倍半萜、倍半萜氧化物组成。非挥发油成分主要含有萜类，除此之外还含有黄酮，香豆素类等化合物。本发明通过研究发现青蒿有免疫抑制和细胞免疫促进等作用。
与现有技术相比，本发明的有益效果为：通过培养青蒿干细胞提取其细胞培养物并制备成干粉，压制成含片，适口性好，方便携带、食用，且可以现在增强免疫力。
具体实施方式
为使本技术领域的技术人员能更好地理解本发明的技术方案，下面结合实施例对本发明技术方案进行详细说明。
下述实施例中所使用的实验方法如无特殊说明，均为常规方法。
下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
1.青蒿干细胞干粉制备
实施例1
青蒿干细胞培养方法参照Paek J S,Jin Y W,Lee E K,et al.Plant stem cellderived from cambium of family asteraceae and method for the isolatedculturing thereof:Europe,EP2436757A2[P].2012-04-04.经扩大培养后将细胞系进行超滤，超滤膜为8000道尔顿，截留大分子团，45HZ超声清洗粉碎，90％乙醇冲洗，70℃旋转蒸发至原体液四分之一，真空冷冻干燥40h，粉碎至120-150目即得青蒿干细胞干粉。
2.增强免疫力口服含片配方
实施例2
一种增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉10份，薄荷脑0.1份，甘草甜素0.2份，麦芽糊精1份，柠檬酸0.8份，硬脂酸镁0.8份，水2份。
实施例3
一种增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉12份，薄荷脑0.2份，甜菊苷0.3份，麦芽糊精2份，柠檬酸1份，硬脂酸镁1份，水3份。
实施例4
一种增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉15份，薄荷脑0.25份，甜茶素0.4份，麦芽糊精3份，柠檬酸1.2份，硬脂酸镁1.2份，水4份。
实施例5
一种增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉28份，薄荷脑0.3份，罗汉果甜0.5份，麦芽糊精4份，柠檬酸1.8份，硬脂酸镁1.8份，水5份。
实施例6
一种增强免疫力的口服含片，由以下重量份比的原料组成：青蒿干细胞干粉30份，薄荷脑0.4份，索马甜0.6份，麦芽糊精5份，柠檬酸2份，硬脂酸镁2份，水6份。
3.甘草甜素制备
以实施例2为例，其使用的甘草甜素的提取方法为：先将甘草切细，和6-8倍量的冷水，浸泡1-1.5d,过滤得到滤液和滤渣。往滤渣中再加入4-6倍量的冷水浸泡10-12h,再次过滤得到滤液。合并两次滤液、蒸发浓缩、冷却,加人乙醇并在低温下放置2.5-3d,将混合液过滤再次蒸发浓缩滤液得到黑褐色粘稠状抽提液。干燥失重在35％以下,甘草抽提液再次浓缩干燥后生成甘草甜素粗结晶,最后将此粗结晶在稀乙醇溶液中进行重结晶即可得到精制的甘草甜素产品。
4.增强免疫力的口服含片制备
以实施例4的配方为例，下面介绍增强免疫力的口服含片制备方法：
(1)制粒，将15份青蒿干细胞干粉、0.4份甜味剂、3份麦芽糊精、1.2份柠檬酸、4份水按重量份比混合好放入制粒机，筛底选20-30目筛；
(2)干燥，制粒结束后，迅速在50-60℃下干燥，当水分在3％～6％之间时，结束干燥；
(3)整粒，将干燥好的颗粒过20-30目筛，使颗粒粒度分布均匀；
(4)混合，加入相应重量份比的清凉剂，硬脂酸镁，在V型混合机中混合5-8min后，装袋备用；
(5)压片，放入进料斗，压片至片剂硬度在80N～110N之间即可。
5.提高免疫力功效验证
选用SPF级昆明种雌性小白鼠72只，6～8周龄(体重18～22g)，取实施例1-7配方所得增强免疫力的口服含片3g，粉碎研磨，配制成20ml样液，备用；小白鼠在实验室条件下适应3d后，随机将72只鼠分为8组，每组12只，每日灌胃给予受试物，给样量根据每周体重增减调整，连续灌胃四周。对照组灌服无菌纯净水。
(1)小鼠迟发型变态反应试验(足跖厚度增加法)
实验结束前的第4d免疫动物，用2％(v/v)绵羊红细胞腹腔注射0.2mL致敏动物，5d后测定左后足跖部厚度，接着于该处皮下注射20％(v/v)绵羊红细胞(20μL/每鼠)，注射后24h测定左后足跖部厚度三次，得平均值，结果见表1。
表1增强免疫力的口服含片对小鼠迟发型变态反应的影响
| 组别 | 足跖增厚/mm |
| 对照组 | 0.48 |
| 实施例2 | 0.62 |
| 实施例3 | 0.65 |
| 实施例4 | 0.63 |
| 实施例5 | 0.62 |
| 实施例6 | 0.64 |
从表1可知，绵羊红细胞诱导的小鼠迟发型变态反应试验(足跖增厚法)，实施例2-6组足跖增厚值与对照组比较，具有显著差异。
(2)NK细胞活性测定(LDH法)
NK细胞活性检测：取浓度为4×105个/mL的YAC-1靶细胞和效应细胞各100μL(效靶比50:1)，加入U型96孔培养板；靶细胞自然释放孔加靶细胞和培养液各100μL，靶细胞最大释放孔加靶细胞和1％NP40各100μL；上述各项均设三个复孔，于37℃、5％CO2培养箱中培养4h，然后将96孔培养板以1500rpm离心5min，每孔吸取上清100μL置平底96孔培养板中，同时加入LDH基质液100μL，反应3min，每孔加入1mol/LHCl 30μL，在酶联仪492nm处测定光密度值，结果见表2.
表2增强免疫力的口服含片对小鼠NK细胞活性的影响
| 组别 | NK细胞活性/％ | NK细胞活性转换值 |
| 对照组 | 8.36 | 0.31 |
| 实施例2 | 13.61 | 0.41 |
| 实施例3 | 13.44 | 0.41 |
| 实施例4 | 13.47 | 0.42 |
| 实施例5 | 13.52 | 0.40 |
| 实施例6 | 13.58 | 0.41 |
从表2可知实施例2-6组的NK细胞活性显著高于对照组，表明增强免疫力的口服含片对受试动物NK细胞活性试验结果为阳性，受试样品具有增强NK细胞活性作用。
显然，上述实施例仅是本发明的部分实施例，而不是全部实施例。基于本发明的启示，本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式，都属于本方面所保护的范围。
Claims (6)
1.一种增强免疫力的口服含片，其特征在于，由以下重量份比的原料组成：青蒿干细胞干粉10-30份，清凉剂0.1-0.4份，甜味剂0.2-0.6份，麦芽糊精1-5份，柠檬酸0.8-2份，硬脂酸镁0.8-2份，水2-6份。
2.根据权利要求1所述增强免疫力的口服含片，其特征在于，由以下重量份比的原料组成：青蒿干细胞干粉12-28份，清凉剂0.2-0.3份，甜味剂0.3-0.5份，麦芽糊精2-4份，柠檬酸1-1.8份，硬脂酸镁1-1.8份，水3-5份。
3.根据权利要求1所述增强免疫力的口服含片，其特征在于，所述清凉剂为薄荷脑。
4.根据权利要求1所述增强免疫力的口服含片，其特征在于，所述甜味剂为甘草甜素、甜菊苷、甜茶素、罗汉果甜或索马甜。
5.根据权利要求4所述增强免疫力的口服含片，其特征在于，所述甘草甜素的提取方法为：先将甘草切细，和6-8倍量的冷水，浸泡1-1.5d,过滤得到滤液和滤渣。往滤渣中再加入4-6倍量的冷水浸泡10-12h,再次过滤得到滤液。合并两次滤液、蒸发浓缩、冷却,加人乙醇并在低温下放置2.5-3d,将混合液过滤再次蒸发浓缩滤液得到黑褐色粘稠状抽提液。干燥失重在35％以下,甘草抽提液再次浓缩干燥后生成甘草甜素粗结晶,最后将此粗结晶在稀乙醇溶液中进行重结晶即可得到精制的甘草甜素产品。
6.根据权利要求1-5任一项所述增强免疫力的口服含片，其特征在于，所述增强免疫力的口服含片制备方法为：
(1)制粒，将青蒿干细胞干粉、甜味剂、麦芽糊精、柠檬酸、水按重量份比混合好放入制粒机，筛底选20-30目筛；
(2)干燥，制粒结束后，迅速在50-60℃下干燥，当水分在3％～6％之间时，结束干燥；
(3)整粒，将干燥好的颗粒过20-30目筛，使颗粒粒度分布均匀；
(4)混合，加入相应重量份比的清凉剂，硬脂酸镁，在V型混合机中混合5-8min后，装袋备用；
(5)压片，放入进料斗，压片至片剂硬度在80N～110N之间即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710012730.7A CN106690321A (zh) | 2017-01-06 | 2017-01-06 | 一种增强免疫力的口服含片 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710012730.7A CN106690321A (zh) | 2017-01-06 | 2017-01-06 | 一种增强免疫力的口服含片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106690321A true CN106690321A (zh) | 2017-05-24 |
Family
ID=58907951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710012730.7A Withdrawn CN106690321A (zh) | 2017-01-06 | 2017-01-06 | 一种增强免疫力的口服含片 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106690321A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872258B2 (en) * | 2018-12-06 | 2024-01-16 | Stemstix, Inc. | Oral cavity treatments |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101791096A (zh) * | 2010-03-30 | 2010-08-04 | 宁夏医科大学 | 沙枣甘饴口含片 |
| CN105770458A (zh) * | 2014-12-22 | 2016-07-20 | 重庆雪瑞盛泉农业开发有限公司 | 一种石斛口含片及其制备方法 |
-
2017
- 2017-01-06 CN CN201710012730.7A patent/CN106690321A/zh not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101791096A (zh) * | 2010-03-30 | 2010-08-04 | 宁夏医科大学 | 沙枣甘饴口含片 |
| CN105770458A (zh) * | 2014-12-22 | 2016-07-20 | 重庆雪瑞盛泉农业开发有限公司 | 一种石斛口含片及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| 周家华等: "《食品添加剂》", 30 April 2001, 化学工业出版社 * |
| 李小芳: "《生物与化学制药综合实训》", 31 July 2016, 武汉大学出版社 * |
| 董漓波: "《家禽常用药物手册》", 31 May 1993, 金盾出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872258B2 (en) * | 2018-12-06 | 2024-01-16 | Stemstix, Inc. | Oral cavity treatments |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oladeji et al. | Phytochemical screening and antimicrobial investigation of Moringa oleifera leaf extracts | |
| Yin et al. | Phytochemical constituents from leaves of Elaeis guineensis and their antioxidant and antimicrobial activities | |
| Osuagwu et al. | The phytochemical composition and antimicrobial activity of Dialium guineense, Vitex doniana and Dennettia tripetala leaves | |
| Shi et al. | Nutrient composition and quality traits of dried jujube fruits in seven producing areas based on metabolomics analysis | |
| KR20110059408A (ko) | 천연 생약재를 포함하는 송아지의 설사병 예방활성을 가지는 사료첨가제의 제조방법 | |
| JP2011032272A (ja) | 複合生薬抽出物を有効成分とする糖尿病または糖尿病合併症の治療または予防用組成物 | |
| DE19834717A1 (de) | Zusammensetzung | |
| Nwachukwu et al. | Comparative evaluation of phytoconstituents, antibacterial activities and proximate contents of fresh, oven dried uncooked and cooked samples of Buchholzia coriacea seed and their effects on hepatocellular integrity | |
| CN107927330A (zh) | 一种治疗鱼类肠炎的中草药饲料添加剂 | |
| Grygorieva et al. | Estimation of phenolic compounds content and antioxidant activity of leaves extracts of some selected non-traditional. | |
| CN103948023B (zh) | 一种增强免疫力及改善睡眠的保健食品及其二步发酵制备方法 | |
| CN111803608A (zh) | 一种具有抗病毒作用的中药组合物 | |
| CN114344351A (zh) | 一种富硒灵芝孢子粉胶囊及其制备方法 | |
| JP5993112B2 (ja) | 抗うつ剤 | |
| CN108938714A (zh) | 发酵黄芪组合物及其制备方法和应用 | |
| CN106690321A (zh) | 一种增强免疫力的口服含片 | |
| CN101411417B (zh) | 蜂胶咀嚼片及生产工艺 | |
| Nnamdi et al. | Hypoglycemic effects of aqueous and ethanolic extracts of dandelion (Taraxacum officinale FH Wigg.) leaves and roots on streptozotocin-induced albino rats | |
| CN103932179B (zh) | 一种缓解压力及护肝的保健食品及其二步发酵制备方法 | |
| Ajibade et al. | Antifungal efficacy of saponin extracted from Phyllanthus niruri | |
| CN109169726A (zh) | 一种含有杀菌效果的复配剂 | |
| CN101248837B (zh) | 一种植物抗菌抗禽流感功能性饲料添加剂 | |
| CN109200233B (zh) | 一种治疗地龙细菌性疾病的药物及其制备方法 | |
| WO2018072276A1 (zh) | 一种保健食品及其制备方法 | |
| Andrade-Cetto et al. | Hypoglycemic effect of the Rhizophora mangle cortex on STZ-NA-induced diabetic rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170524 |